The gallium complex KP46 sensitizes resistant leukemia cells and overcomes Bcl-2-induced multidrug resistance in lymphoma cells via upregulation of Harakiri and downregulation of XIAP in vitro

The gallium complex KP46 sensitizes resistant leukemia cells and overcomes Bcl-2-induced multidrug resistance in lymphoma cells via upregulation of Harakiri and downregulation of XIAP in vitro

Tris-(8-quinolinolato)gallium(III) (KP46, AP-002) is an orally administered investigational anticancer and bone-protective drug currently being evaluated in patients with advanced solid tumors with bone involvement. Despite the clinical efficacy of other gallium compounds in non-Hodgkin’s lymphoma,...

Full description

Bibliographic Details
Main Authors: Nicola L. Wilke, Liliane Onambele Abodo, Corazon Frias, Jerico Frias, Jennifer Baas, Michael A. Jakupec, Bernhard K. Keppler, Aram Prokop
Format: Article
Language:English
Published: Elsevier 2022-12-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Cancer chemotherapy
Gallium
Leukemia
Lymphoma
Multidrug resistance
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332222013634

Internet

http://www.sciencedirect.com/science/article/pii/S0753332222013634

Similar Items